Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy Safety and Efficacy Results of a Phase II-A Randomized Trial

被引:141
作者
Butler, Javed [1 ]
Epstein, Stephen E. [2 ]
Greene, Stephen J. [3 ]
Quyyumi, Arshed A. [4 ]
Sikora, Sergey [5 ]
Kim, Raymond J. [3 ]
Anderson, Allen S. [6 ]
Wilcox, Jane E. [6 ]
Tankovich, Nikolai I. [7 ]
Lipinski, Michael J. [2 ]
Ko, Yi-An [8 ]
Margulies, Kenneth B. [9 ]
Cole, Robert T. [4 ]
Skopicki, Hal A. [1 ]
Gheorghiade, Mihai [10 ]
机构
[1] SUNY Stony Brook, Dept Med, Div Cardiol, Stony Brook, NY 11794 USA
[2] MedStar Washington Hosp Ctr, MedStar Heart & Vasc Inst, Washington, DC USA
[3] Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA
[4] Emory Univ, Dept Med, Div Cardiol, Atlanta, GA 30322 USA
[5] CardioCell LLC, San Diego, CA USA
[6] Northwestern Univ, Dept Med, Div Cardiol, Feinberg Sch Med, Chicago, IL 60611 USA
[7] Stemedica Cell Technol Inc, San Diego, CA USA
[8] Emory Univ, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA
[9] Univ Penn, Dept Med, Div Cardiol, Perelman Sch Med, Philadelphia, PA 19104 USA
[10] Northwestern Univ, Ctr Cardiovasc Innovat, Feinberg Sch Med, Chicago, IL 60611 USA
关键词
cardiomyopathy; clinical trial; heart failure; nonischemic; stem cells; viable myocardium; HOSPITALIZED HEART-FAILURE; 6-MINUTE WALK TEST; EJECTION FRACTION; DRUG DEVELOPMENT; DYSFUNCTION; THERAPY; HEALTH; DEATH;
D O I
10.1161/CIRCRESAHA.116.309717
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Rationale: Potential benefits of mesenchymal stem cell (MSC) therapy in heart failure may be related to paracrine properties and systemic effects, including anti-inflammatory activities. If this hypothesis is valid, intravenous administration of MSCs should improve outcomes in heart failure, an entity in which excessive chronic inflammation may play a pivotal role. Objective: To assess the safety and preliminary efficacy of intravenously administered ischemia-tolerant MSCs (itMSCs) in patients with nonischemic cardiomyopathy. Methods and Results: This was a single-blind, placebo-controlled, crossover, randomized phase II-a trial of nonischemic cardiomyopathy patients with left ventricular ejection fraction <= 40% and absent hyperenhancement on cardiac magnetic resonance imaging. Patients were randomized to intravenously administered itMSCs (1.5x10(6) cells/kg) or placebo; at 90 days, each group received the alternative treatment. Overall, 22 patients were randomized to itMSC (n=10) and placebo (n=12) at baseline. After crossover, data were available for 22 itMSC patients. No major differences in death, hospitalization, or serious adverse events were noted between the 2 treatments. Change from baseline in left ventricular ejection fraction and ventricular volumes was not significantly different between therapies. Compared with placebo, itMSC therapy increased 6-minute walk distance (+36.47 m, 95% confidence interval 5.98-66.97; P=0.02) and improved Kansas City Cardiomyopathy clinical summary (+5.22, 95% confidence interval 0.70-9.74; P=0.02) and functional status scores (+5.65, 95% confidence interval -0.11 to 11.41; P=0.06). The data demonstrated MSC-induced immunomodulatory effects, the magnitude of which correlated with improvement in left ventricular ejection fraction. Conclusions: In this pilot study of patients with nonischemic cardiomyopathy, itMSC therapy was safe, caused immunomodulatory effects, and was associated with improvements in health status and functional capacity.
引用
收藏
页码:332 / +
页数:12
相关论文
共 22 条
[1]
The Global Health and Economic Burden of Hospitalizations for Heart Failure Lessons Learned From Hospitalized Heart Failure Registries [J].
Ambrosy, Andrew P. ;
Fonarow, Gregg C. ;
Butler, Javed ;
Chioncel, Ovidiu ;
Greene, Stephen J. ;
Vaduganathan, Muthiah ;
Nodari, Savina ;
Lam, Carolyn S. P. ;
Sato, Naoki ;
Shah, Ami N. ;
Gheorghiade, Mihai .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (12) :1123-1133
[2]
[Anonymous], J CARDIOVASC MED HAG
[3]
Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT [J].
Barsheshet, Alon ;
Goldenberg, Ilan ;
Moss, Arthur J. ;
Eldar, Michael ;
Huang, David T. ;
McNitt, Scott ;
Klein, Helmut U. ;
Hall, W. Jackson ;
Brown, Mary W. ;
Goldberger, Jeffrey J. ;
Goldstein, Robert E. ;
Schuger, Claudio ;
Zareba, Wojciech ;
Daubert, James P. .
EUROPEAN HEART JOURNAL, 2011, 32 (13) :1622-1630
[4]
Molecular and Cellular Basis of Viable Dysfunctional Myocardium [J].
Bayeva, Marina ;
Sawicki, Konrad Teodor ;
Butler, Javed ;
Gheorghiade, Mihai ;
Ardehali, Hossein .
CIRCULATION-HEART FAILURE, 2014, 7 (04) :680-691
[5]
PREDICTION OF MORTALITY AND MORBIDITY WITH A 6-MINUTE WALK TEST IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION [J].
BITTNER, V ;
WEINER, DH ;
YUSUF, S ;
ROGERS, WJ ;
MCINTYRE, KM ;
BANGDIWALA, SI ;
KRONENBERG, MW ;
KOSTIS, JB ;
KOHN, RM ;
GUILLOTTE, M ;
GREENBERG, B ;
WOODS, PA ;
BOURASSA, MG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (14) :1702-1707
[6]
The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure [J].
Cahalin, LP ;
Mathier, MA ;
Semigran, MJ ;
Dec, GW ;
DiSalvo, TG .
CHEST, 1996, 110 (02) :325-332
[7]
Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial [J].
Cleland, JGF ;
Pennell, DJ ;
Ray, SG ;
Coats, AJ ;
Macfarlane, PW ;
Murray, GD ;
Mule, JD ;
Vered, Z ;
Lahiri, A .
LANCET, 2003, 362 (9377) :14-21
[8]
Developing New Treatments for Heart Failure Focus on the Heart [J].
Gheorghiade, Mihai ;
Larson, Christopher J. ;
Shah, Sanjiv J. ;
Greene, Stephen J. ;
Cleland, John G. F. ;
Colucci, Wilson S. ;
Dunnmon, Preston ;
Epstein, Stephen E. ;
Kim, Raymond J. ;
Parsey, Ramin V. ;
Stockbridge, Norman ;
Carr, James ;
Dinh, Wilfried ;
Krahn, Thomas ;
Kramer, Frank ;
Wahlander, Karin ;
Deckelbaum, Lawrence I. ;
Crandall, David ;
Okada, Shunichiro ;
Senni, Michele ;
Sikora, Sergey ;
Sabbah, Hani N. ;
Butler, Javed .
CIRCULATION-HEART FAILURE, 2016, 9 (05)
[9]
REPLY: Considerations for Drug Development for Heart Failure [J].
Greene, Stephen J. ;
Gheorghiade, Mihai .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) :1061-1062
[10]
Matching Mechanism of Death With Mechanism of Action Considerations for Drug Development for Hospitalized Heart Failure [J].
Greene, Stephen J. ;
Gheorghiade, Mihai .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (15) :1599-1601